Announcements
- Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
- Ocugen to Present at BIO International Convention 2024
- Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
- Ocugen Provides Business Update with First Quarter 2024 Financial Results
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
- Ocugen to Present at May 2024 Investor Conferences
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
More ▼
Key statistics
On Friday, Ocugen Inc (OCGN*:MEX) closed at 28.00, -17.01% below its 52-week high of 33.74, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.25 |
---|---|
High | 28.00 |
Low | 27.25 |
Bid | 27.00 |
Offer | 33.00 |
Previous close | 27.50 |
Average volume | 179.50 |
---|---|
Shares outstanding | 257.33m |
Free float | 253.26m |
P/E (TTM) | -- |
Market cap | 445.18m USD |
EPS (TTM) | -0.2348 USD |
Data delayed at least 20 minutes, as of May 31 2024 19:02 BST.
More ▼